35 results about "Vitamin binding" patented technology

The invention provides a subspace fusion-based protein-vitamin binding location point predicting method. The method comprises the steps of feature extracting and feature combining: extracting evolution information, secondary-level structural information the binding tendency information of a protein by respectively using a PSI-BLAST, a PSIPRED and a protein-vitamin binding location point tendency table, and converting amino acid residues in a protein sequence into a vector presentation mode by a sliding window and serial combination; using a multi-feature selection algorithm to perform feature selection on an original feature space for multiple times; forming a feature subspace by feature subsets obtained from feature selection every time and establishing multiple feature subspaces; training one SVM (support vector machine) classifier for each obtained feature subspace; fusing multiple SVM classifiers which are trained by a weighted average classifier fusing mode; performing protein-vitamin binding location prediction on the protein to be predicted based on a fused SVM predictor. The prediction method is fast in prediction sped and high in prediction precision.

The present invention is directed to compositions and devices for transdermally administering vitamin B₁₂ to a subject. In one aspect, a vitamin B₁₂ containing composition suitable for transdermal administration is provided in the form of a shelf stable transdermal delivery patch. Such patches contain vitamin B₁₂ combined with selected penetration enhancers and vitamin B₁₂ stabilizers.

It has been demonstrated that one of Vitamin D Binding Protein (DBP) biological functions is to enhance the chemotactic activity of C5a and C5a des Arg. The present invention has found that peptides having sequences that substantially correspond to a specific region in the N-terminal domain I of DBP can block the DBP enhancement of C5a or C5a des Arg chemotactic activity. Based in this discovery the present invention provides DBP antagonist peptides and the use thereof for the treatment C5a or C5a des Arg-mediated disorders.

The invention discloses a dissociation method of 25-hydroxyvitamin D binding protein. The dissociation method comprises the following steps: preparing a mother solution, taking a serum sample, addingthe mother solution, carrying out vortex mixing for 1min, uniformly mixing the obtained solution, allowing the obtained mixed solution to stand for 5min, and centrifuging the mixed solution in a centrifuge; and taking the obtained supernatant of the solution, adding ethanol, carrying out vortex mixing, allowing the obtained mixed solution to stand, placing the obtained solution in the centrifuge,centrifuging the solution, taking the obtained supernatant, placing the supernatant in a new centrifuge tube, blow-drying the supernatant by using a nitrogen blow-drying instrument, adding a separation mobile phase, re-dissolving the dried supernatant, uniformly mixing the re-dissolved supernatant and the separation mobile phase, and carrying out LC-MS/MS detection. The solution uses dithiothreitol with a certain concentration, so the 25-hydroxyvitamin D to be analyzed can be well separated, the detection result of the 25-hydroxyvitamin D can be improved, and the overall content of the vitaminD is further determined; and the dithiothreitol has strong reducibility, so the stability of the 25-hydroxyvitamin D in the purification and extraction process is improved.

The present invention relates to beta-lactoglobulin-vitamin conjugate comprising sugar alcohols. The conjugate comprises beta-lactoglobulin, VE, sorbitol and maltitol which are subjected to high-pressure pulse glycosylation treatment. The high-pressure pulse glycosylation treatment means that a phosphate buffer solution with a concentration of 0.01 mol/L and a pH value of 7.4 is treated in a high-voltage electric field for 80 microseconds so as to obtain the beta-lactoglobulin with a concentration of 1 mg/mL. The electric field intensity of the high-voltage electric field is 30 kV/cm, and theelectric field waveform is unipolar square wave. The invention also discloses a preparation method of the beta-lactoglobulin-vitamin conjugate comprising the sugar alcohols. According to the invention, the beta-lactoglobulin is modified after the high-pressure pulse glycosylation treatment, so that the secondary structure and the tertiary structure of the beta-lactoglobulin are forced to be changed, the allergenicity of protein is effectively reduced, and meanwhile, natural emulsifiers of the sugar alcohols are added to improve the combination binding rate.

This invention relates to the targeted delivery of cytotoxic drugs A) to lymphocytes responsible for the rejection of transplanted tissues, such as kidneys or hearts or bone marrow cells; B) the use of a non-toxic naturally existing delivery system to transport high concentrations of radiosensitizers to cancer cells; and C) to the targeted delivery of drugs in medical diagnosis and treatment of cancer.

Vitamin B₁₂ can be conjugated to anti-cancer drugs to deliver these drugs selectively to tumors, wherein the conjugates bind to transcobalamin. The complex of vitamin B₁₂ and transcobalamin is recognized and taken into cells by specific cell surface receptors which are overexpressed in rapidly dividing cells.

The invention discloses a preparation method of a nano-diamond beauty makeup product, and belongs to the field of diamond application. The preparation method comprises the following four parts: strong acid treatment of the nano-diamond, N2 atmosphere vacuum heat treatment, surface functionalization treatment of the nano-diamond, and combination of the nano-diamond and vitamin C. The method is simple to operate, the product has the properties of low toxicity, biocompatibility, chemical inertness, fluorescence effect and the like, and the nano-diamond can be combined with the skin surface, so that the transdermal moisture loss is reduced, the function of the water lipid skin surface is influenced, and the skin is protected from aging.

The invention discloses a preparation method of a stable vitamin A preparation. The preparation method includes following steps: (1) activating attapulgite and performing high-temperature treatment to the attapulgite; and (2) adding the treated attapulgite in a vitamin A ethanol solution for adsorption. In the invention, the attapulgite is treated through acid and then treated at a high temperature to form activated attapulgite, and then the activated attapulgite is combined with vitamin A. The preparation is good in stability. The fat-soluble vitamin which is difficult to disperse is prepared into solid powder, so that the defect of vitamin A is overcome. The vitamin A preparation is convenient to use and is an excellent raw material for producing feeds without technical limit.

The invention discloses a synthesis method and application of an miRNA-carrying VB12 binding type nano-composite. The synthesis method comprises the following steps: mixing and dissolving a PLGA-PEG nano-composite, vitamin B12, EDC and DMAP in an anhydrous solvent A, and performing stirring for reaction at 15-40 DEG C; and after the reaction is finished, performing dialyzing, and removing the solvent to obtain the vitamin B12 combined nano-composite. The synthesis method has the advantages of mild preparation conditions, cheap required raw materials, convenient operation, simple process, highefficiency and practicability. The prepared nano-composite optimizes nucleic acid drugs from three aspects of water solubility, stability and tumor targeting, endows the nucleic acid drugs with efficient and low-toxicity anti-tumor effects, and has a wide application prospect in the field of tumor treatment.

A buffer solution includes methanol and the at least one fluoroalkyl surfactant selected from perfluorocarboxylic acids, perfluorosulfonic acids and their salts. A method for detecting and quantifying, in vitro, vitamin D and/or at least one vitamin D metabolite in a biological sample includes treating the sample by incorporating at least one fluoroalkyl surfactant and methanol so as to dissociate the vitamin D and/or its metabolite(s) to be detected from vitamin D binding protein; and detecting and quantifying vitamin D and/or at least one of its metabolites, in particular by immunoassay. A kit for detecting and quantifying vitamin D and/or at least one vitamin D metabolite by immunoassay and including the solution is provided.

The invention relates to a urine protein marker for asthma and application thereof. The present application relates to the application of a urine protein marker selected from a group consisting of epidermal growth factor receptor substrate 15, Cathelicidin antimicrobial peptide, haptoglobin, alpha-1-acidic glycoprotein 1, prolactin-inducing protein homolog, odorant binding protein 2a, protein LEG1homolog, complement factor B, retinoid beta, beta-2 microglobulin, prothrombin, eosinophilic granulocyte cationic protein 1, protein AMBP, plasminogen, a procollagen C-endopeptidase enhancer 1, a sodium channel and gridding protein connecting agent 1 and vitamin D binding protein. According to the application, an animal model for screening the asthma-related urine protein marker is established, the asthma-related urine protein marker is obtained by using the established animal model, and an application of a detection reagent of the marker in preparation of a kit for diagnosing asthma of a subject is also established.

The present invention relates to a composition for treating and preventing degenerative brain diseases comprising a complex of vitamin C and an aptamer binding to the vitamin C as an active ingredient, and the composition of the present invention has improved and therapeutic effects in a Parkinson's disease experimental model and so the composition of the present invention can be used as medicines and health functional foods for patients with degenerative brain diseases including Parkinson's disease.

Method of diagnosis and prognosis of contrast media induced nephropathy (CIN) comprising the steps of i) taking a urine sample from a patient exposed to the application of contrast media, notably patients subjected to coronary angiography; ii) assessing the level of vitamin D binding protein (VDBP) in the urine sample obtained in step (i); iii) relating the urinary vitamin D binding protein level determined in step (ii) to a pre-selected threshold level, wherein a urinary vitamin D binding level higher than said pre-selected threshold level indicates that the patient is at risk of renal failure and in need of a dialysis treatment.

The present invention relates to a composition for alleviating and treating hair loss, hair damage, and a skin disease of an animal, comprising vitamin C and an aptamer binding to vitamin C as active ingredients, and, as alleviation and treatment effects were present in all subjects with hair loss, hair damage, atopic dermatitis, eczema, and contact dermatitis, when treated with the composition of the present invention, the composition can be used as a drug, cosmetic product, etc. for subjects with the conditions.

The present invention relates to an eye drop composition comprising, as active ingredients, vitamin C and an aptamer bonding to the vitamin C. As can be known from the present invention, the eye drop composition comprising aptamin C, of the present invention, enables the maintaining of a low ROS level and the improvement of epithelial cell damage and an inflammatory response, and thus, by using an aptamer and antioxidant conjugate for maintaining such antioxidant effect for a long time, an effect of improving and treating dry eye syndrome may be achieved.